Skip to main content
Premium Trial:

Request an Annual Quote

FTC Seeks To Nix Cytyc s Acquisition of Digene

NEW YORK, June 25-The Federal Trade Commission yesterday said it would seek to block Cytyc's acquisition of Digene as a violation of federal antitrust laws.


The acquisition, said the FTC, would lead to decreased competition in the highly concentrated market for cervical cancer diagnostics.


FTC staff will now seek a court injunction to block the purchase, and plan to file a motion with the federal district courts by Thursday, June 27.


Liquid Pap tests are the most commonly used primary screen for cervical cancer, and Cytyc dominates this market with a 93 percent share. Digene is the only U.S. company to offer a DNA-based diagnostic for human papilloma virus, the pathogen believed to cause the disease.


Digene's HPV test is now only offered as a follow-up to clarify Pap test results, but the company is seeking permission to market the test as a primary screen in conjunction with a traditional Pap smear, and as a stand-alone test.


Cytyc announced its plans to acquire Digenein February.


By mid-morning today, Cytyc shares had plummeted nearly 30 percent from yesterday's close, slipping from $11.46 yesterday to $8.05 this morning. Digene's share price had fallen from $12.69 at yesterday's close to $10.85 mid-morning today, down 14.5 percent.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.